A phase II, open-label, multicentre, randomised, comparator study of substitution with tenofovir [tenofovir disoproxil fumarate] or abacavir in HIV-1 infected individuals, with a viral load less than 50 copies/mL, receiving a thymidine analogue (zidovudine or stavudine) as part of their highly active antiretroviral therapy

Trial Profile

A phase II, open-label, multicentre, randomised, comparator study of substitution with tenofovir [tenofovir disoproxil fumarate] or abacavir in HIV-1 infected individuals, with a viral load less than 50 copies/mL, receiving a thymidine analogue (zidovudine or stavudine) as part of their highly active antiretroviral therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2008

At a glance

  • Drugs Abacavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms RAVE
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 21 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top